Rubius Therapeutics, an early-stage company developing an entirely new class of medicines based on red blood cell therapeutics, was operating largely in ‘stealth mode’. Ahead of its Series B financing announcement, the company wanted to refine its company narrative, raise its visibility in the industry, forge relationships with media and investors, and update its digital presence to reflect its cutting-edge science and innovative culture.
Through collaboration with the Rubius team, Pure conducted a messaging workshop to help shape and refine a corporate narrative that refined the company’s positioning, its culture, and values.
Once defined, the Rubius narrative was deployed through a strategic communications plan across audiences to enhance visibility of Rubius and its leadership team.
Pure leveraged existing relationships with financial, regional and industry reporters to secure immediate coverage, introduce Rubius executives to key media outlets and further educate on the company’s science and business goals.
To establish Rubius and present a new “face” for the company, Pure designed, developed and launched.
- Successfully announced the company’s Series B financing with the distribution of a press release and extensive embargoed media outreach strategy; Rubius leadership received widespread media interest and coverage in top-tier outlets, including The Boston Globe, Reuters and Fortune.
- Transformed the company’s website from a starter site to a customized, functional and dynamic site fit for a company pioneering the next generation of medicines.